enzh-TWfrdeitjaptrues

Steven P. Treon, MD, PhD, has been promoted to professor of medicine at Harvard Medical School (HMS). Treon earned a doctorate in tumor immunology from Boston University (BU) and his medical degree from BU School of Medicine. He completed an internship in medicine and a residency in internal medicine at BU Medical Center. He also completed a clinical fellowship in hematology and oncology at Massachusetts General Hospital and a research fellowship at Dana-Farber and HMS.

His research focuses on understanding the genetic basis and pathogenesis of Waldenström’s macroglobulinemia and developing therapeutics for the condition. Treon is the director of Dana-Farber’s Bing Center for Waldenström’s Macroglobulinemia.

Discoveries in his laboratory on the role of key mutations in Waldenstrom’s led to the first breakthrough designation by the Food and Drug Administration (FDA) for accelerated approval of the targeted drug ibrutinib for treatment of the disease. Treon also served as principal investigator of the pivotal trial supporting FDA approval of ibrutinib for Waldenstrom’s. He has led other clinical trials resulting in the adoption of novel therapeutics and combination therapies for the disease.

Treon has published more than 250 original articles, reviews, reports, and book chapters. He has received numerous awards for his clinical and research efforts, including an ASCO Young Investigator Award, the Robert A. Kyle Award, designation as “America’s Top Doctor” by U.S. News and World Report, and “Best of ASH” recognitions in 2011 and 2013 at the annual meeting of the American Society of Hematology.

Above photo (left to right): Pasi Janne, Stephen Nodi, Ursula Matulonis, Steven Treon, Loren Walensky, David Reardon

Home Page photo: Steven Treon and Barbara McNeil

Latest Bing Center News

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial

Researchers say ibrutinib seems to protect those with COVID-19 from lung damage and respiratory distress. They will now conduct a trial to see if the medication can reduce a patient’s need for a ventilator, improve survival and reduce their time in the hospital.

Read more..

COVID-19 Information for Our Patients

COVID-19 Information for Our Patients

The Bing Center would like to share this important information with all of our patients and interested parties to help us all manage through this unprecedented crisis in the best and most productive way possible.

Read more..

Waldenström Macroglobulinemia Specialty Channel

Waldenström Macroglobulinemia Specialty Channel

Welcome to the Oncology Learning Network Waldenstrom Macroglobulinemia Specialty Channel. Here you will find articles dedicated to the research and treatment of WM.

Read more..

Dana-Farber to Test Blood Cancer Drug in COVID-19

Dana-Farber to Test Blood Cancer Drug in COVID-19

Scientists at Dana-Farber have launched a clinical test of a blood-cancer drug in patients that have the COVID-19 virus. The test follows several case reports in which the drug, ibrutinib, appeared to protect against lung damage and respiratory distress caused by the novel virus.

Read more..

BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™

Read more..

Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies

Understanding Waldenström's Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and Emerging Therapies

We are excited to announce this new webcast on diagnosis, risk stratification, and current and emerging therapies for Waldenström's Macroglobulinemia (WM).

Read more..

Watch Dr. Jorge Castillo’s engaging “Ask the Doctor” session

Watch Dr. Jorge Castillo’s engaging “Ask the Doctor” session

Fifty WMers from the Philly WM Support Group enjoyed a lively, engaging and informative conversation with Dr. Jorge Castillo, Clinical Director of the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute.

Read more..

Drs. Castillo and Kastritis have joined the IWMF Scientific Advisory Committee

Drs. Castillo and Kastritis have joined the IWMF Scientific Advisory Committee

The IWMF is proud to welcome two new members to its Scientific Advisory Committee (SAC) chaired by Dr. Steven Ansell of the Mayo Clinic and Dr. Stephen Treon of the Dana-Farber Cancer Institute. The new members, Dr. Jorge Castillo from Dana-Farber, Boston, USA, and Dr. Efstathios Kastritis of Athens, Greece, were invited to participate because of their expertise in specific research areas identified by the IWMF-LLS Strategic Research Roadmap for WM.

Read more..

Waldenstrom's Song - Tim Salz, UC Berkeley, CA

Waldenstrom's Song - Tim Salz, UC Berkeley, CA

This is a song I wrote for all of my fellow Wallies out there. Thanks for watching.

Read more..

Robert J. Manning, FM, RNG

Robert J. Manning, FM, RNG

I first met Bob Manning in early 2004 when I started volunteering at the Bing Center. My boss introduced me to Bob, and said 3 words, "Help this guy". The first thing I noticed was Bob's badge, which contained his name, followed by the credentials, FM, RNG. Bob told me they meant, "Former Marine, Real Nice Guy". That's when I knew this wasn't going to be a boring relationship.

Read more..